Introducing ByonGuard: Conditional Activation Technology that Improves the Safety Profile & Therapeutic Index of ADCs
- Demonstrating rationale to develop conditionally active ADCs to overcome challenges with target mediated toxicity and improve therapeutic index
- Laying out ADC masking mechanism leveraging steric masking nanobody peptide activated by a variety of proteases in the tumor
- Highlighting development of ADCs leveraging masking technology including preclinical efficacy and safety profiles